Filing Flows › Ovid Therapeutics (OVID) › Q4 2025 › vs Q3 2025
Ovid Therapeutics (OVID) Q4 2025 vs Q3 2025 (quarter over quarter)
Ovid Therapeutics's revenue rose $586K (+444%) from $132K in Q3 2025 to $718K in Q4 2025.
Ovid Therapeutics, Q4 2025: revenue $718K (+845% year over year), net earnings $9.7M, operating cash flow −$10.4M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q4 2025 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $718K | $132K | $586K | +444% |
| Other income, net | $22.0M | $365K | $21.6M | 60× |
| Costs & expenses | $22.7M | $12.7M | $10.0M | +79% |
| Operating costs | $13.0M | $12.7M | $356K | +3% |
| Net earnings | $9.7M | −$12.2M | $21.8M | — |
| Research & development | $6.6M | $5.9M | $719K | +12% |
| General & admin | $6.4M | $6.8M | −$363K | -5% |
| Operating cash sources | $21.3M | $1.8M | $19.4M | 12× |
| Depreciation & amortization | $17K | $16K | $1K | +6% |
| Share-based compensation | $1.2M | $1.1M | $86K | +8% |
| Cash used in operations | $10.4M | $12.9M | −$2.5M | -19% |
| Working capital & other | $21.3M | $1.8M | $19.4M | 12× |
Questions
How much did Ovid Therapeutics's revenue grow quarter over quarter in Q4 2025?
Ovid Therapeutics's revenue rose $586K (+444%) from $132K in Q3 2025 to $718K in Q4 2025.